Absolute Requirement of CD11/CD18 Adhesion Molecules, FcRII, and the Phosphatidylinositol-Linked FcRIII for Monoclonal Antibody-Mediated Neutrophil Antihuman Tumor Cytotoxicity

By Brian H. Kushner and Nai-Kong V. Cheung

We have previously shown that 3F8, a murine IgG, monoclonal antibody (MoAb) specific for the ganglioside Gd₃, mediates tumor cell kill in vitro and in vivo. We now describe receptor requirements of polymorphonuclear leukocytes (PMN) in 3F8-mediated cytotoxicity (ADCC) of human Gd₃(+) melanoma and neuroblastoma cell lines. PMN from a child with leukocyte adhesion deficiency (LAD) were devoid of CD11/CD18 adhesion molecules and mounted no detectable ADCC. MoAb to CD11b, CD11c, and CD18 each efficiently blocked ADCC by normal PMN. In contrast, a panel of different MoAbs to CD11a had no significant inhibitory effect on ADCC, a finding consistent with the low-to-absent expression of the CD11a ligand, intercellular adhesion molecule-1, on the target cells. Granulocyte-macrophage colony-stimulating factor (GM-CSF) significantly increased the expression of CD11b, CD11c, and CD18 on normal PMN, decreased the expression of Fc receptors (FcR), and enhanced ADCC by normal but not by LAD PMN. MoAbs to FcRII and FcRIII each efficiently blocked ADCC; anti-FcRI MoAb had no effect. Flow cytometry using anti-FcRII MoAb versus anti-FcRIII MoAb did not show cross competition, suggesting that inhibition of ADCC was not a steric effect resulting from FcRII proximity to FcRII. PMN deficient in FcRII (obtained from patients with paroxysmal nocturnal hemoglobinuria) and PMN depleted of FcRII by treatment with elastase or phosphatidylinositol (PI)-specific phospholipase C produced low ADCC, supporting a role for the PI-linked FcRII. Thus, optimal ADCC using human PMN, human solid tumor cells, and a clinically active MoAb (conditions that contrast with the heterologous antibodies and nonhuman or nonneoplastic targets used in most models of PMN ADCC) required CD11b, CD11c, FcRII, and the PI-linked FcRIII. Furthermore, in this clinically relevant system, GM-CSF enhancement of antitumor PMN ADCC correlated with increased expression of CD11/CD18 molecules.

3F8 IS A MURINE IgG, monoclonal antibody (MoAb) that is well-suited for targeted immunotherapy of cancer because (1) its ganglioside Gd₃ target antigen is highly restricted to neuroectodermal tissues and is genetically stable; (2) it has excellent tumor localization in patients; and (3) in vitro, it mediates human tumor cell destruction by human complement and by human lymphocytes, cultured monocytes, and polymorphonuclear leukocytes (PMN). This constellation of features, which may account for regressions of Gd₃(+) tumors in patients treated with 3F8, has been documented in very few MoAbs. For example, most studies of antibody-dependent cellular cytotoxicity (ADCC) use mononuclear cells as effectors, in part because few MoAbs (clinically applicable or otherwise) are known to mediate ADCC of human tumor cells by PMN. Yet, in vivo, PMN are the predominant circulating leukocyte and are activated and increased in number by cytokines such as granulocyte-macrophage colony-stimulating factor (GM-CSF). Studies showing PMN ADCC of human tumor cells mediated by heterologous antibodies are also few in number. Other studies of antitumor PMN ADCC have used heterologous antibodies and nonhuman, usually lymphohematopoietic, targets. The cytotoxic mechanisms in these model systems may differ from those operative in PMN ADCC of human solid tumor cells that not only are large in size, and hence may not be readily phagocytosed by PMN, but are also relatively resistant to reactive oxygen species.

The current study focused on receptor requirements of 3F8-mediated PMN ADCC of Gd₃(+) human melanoma and neuroblastoma cells. Although CD11/CD18 molecules mediate a wide range of adhesion-dependent activities of PMN, no report to date has described the involvement of this complex in PMN ADCC of human tumor cells. The same holds for Fc receptors (FcR), despite the well-established necessity of FcR in ADCC. Of the three reported types of FcR, the low-affinity FcRII and FcRIII predominate on resting PMN. While FcRII has a well-documented role in many PMN activities, the importance of the more abundant FcRII, including in ADCC, is uncertain, given its linkage to PMN via a phosphatidylinositol (PI) moiety. This form of linkage, in contrast to the polypeptide anchor of FcRII, lacks a transmembrane connection to the cytoplasm and may limit the capacity of FcRII to transmit intracellular signals for PMN function. We now demonstrate a critical role in a clinically relevant model of PMN ADCC, not only for FcRII and all subunits of the CD11/CD18 complex, except CD11a, but also for the PI-linked FcRIII.

MATERIALS AND METHODS

MoAbs. Purified 3F8 (anti-Gd₃; IgG₂) was prepared in our laboratory as described, and was used at a final concentration of 2 μg/mL, unless otherwise stated. A110 (anti-decay accelerating factor [DAF]) was the gift of Dr M.E. Medof (Case Western Reserve University, Cleveland, OH). 197 (anti-FcRI; IgG₃), prepared by hollow-fiber tubing, was the gift of Dr M.W. Fanger.

From the Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY.

Submitted May 14, 1991; accepted November 15, 1991.

Supported by grants from the National Institutes of Health (CA 33049), the American Cancer Society (IM 521 and CDA 90-242), the Robert Steel Foundation, and the Justin Zahn Fund. B.H.K. is the recipient of an American Cancer Society Career Development Award.

Presented in part at the 32nd Annual Meeting of the American Society of Hematology, Boston, MA, November 28–December 4, 1990.

Address reprint requests to Brian H. Kushner, MD, Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. section 1734 solely to indicate this fact.

© 1992 by The American Society of Hematology.

Blood, Vol 79, No 6 (March 15), 1992: pp 1484-1490
Rothlein (Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT), and 3.9 (anti-CD11c; IgG2a) as ascites, was obtained from Becton Dickinson Laboratories (Mountain View, CA) and J. Ritz (Dana-Farber Cancer Center, Boston, MA). Purified IB4 (anti-CD11b; IgG2b) was the gift of Dr R.F. Todd (University of Michigan, Ann Arbor, MI). Purified IB4 (anti-CD11b; IgG2b) was the gift of Dr J. Unkeless (Mt Sinai Medical School, New York, NY), and 2F12 (IgG1) was a gift, respectively, of Drs A.M. Krensky (Stanford University, Palo Alto, CA) and J. Ritz (Dana-Farber Cancer Center, Boston, MA). Purified OMK-1 (IgG4) and OKM-10 (IgG2a) (both anti-CD11b) were gifts of Dr P. Rao (Ortho Diagnostics, Raritan, NJ). LM2/1 (anti-CD11b; IgG2a), and TS1/18 (anti-CD18; IgG4) were gifts of Dr T. Springer (Harvard University, Boston, MA). The following were obtained as hybridomas from the American Type Culture Collection (ATCC; Rockville, MD): IV.3 (anti-FcRII; IgG1), 42 TS1/22 (anti-CD11a; IgG2a) and BBM.1 (anti-CD18; IgG2a) were kindly provided as a hybridoma by Dr J. Unkeless (Mt Sinai Medical School, New York, NY). Hybridomas were grown as ascites in BALB/c mice, and partially purified by precipitation in 45% ammonium sulfate at 0°C, followed by dialysis against phosphate-buffered saline.

Cell lines. LAN-1 and IMR-6 (both neuroblastoma) were gifts, respectively, of Dr R. Seeger (University of Southern California, Los Angeles, CA) and Dr R.K. Liao (McMaster University, Ontario, Canada). SKMel-1 (melanoma) was generously provided by Dr Martin Low (Columbia University, New York, NY). Recombinant human GM-CSF was a gift from Genetics Institute (Cambridge, MA).

RESULTS

Requirement for CD11/CD18 adhesion molecules. Experiments reported elsewhere25 showing no lysis of "innocent bystander" Gm1(-) tumor cell targets suggested a requirement for physical attachment between effector and target cells in 3F8-mediated PMN ADCC, which is a nonphagocytic process (Munn D.H., Kushner B.H., unpublished observations, April 1990). In the current study, results using LAD PMN established the importance of CD11/CD18 molecules in this system. LAD PMN, which were confirmed by immunophenotyping to be devoid of the entire CD11/CD18 complex, mounted no detectable ADCC (Table 1). The addition of GM-CSF did not alter this result, even though in parallel assays GM-CSF enhanced ADCC by normal PMN, as previously observed,4 and increased the expression of CD11/CD18 on normal PMN (see below).

To identify which CD11/CD18 subunits were required for 3F8-mediated PMN ADCC, subunit-specific MoAbs were added to the ADCC assay (Fig 1). MoAbs to CD11b (LM2/1, Mol), CD11c (LeuM5, 3.9), and CD18 (R15.7, IB4, TS1/18) each produced efficient concentration-independent ADCC; however, CD18 was not required for 3F8-mediated PMN ADCC (Table 1).

Table 1. LAD Versus Normal PMN in 3F8-Mediated ADCC

| Target   | E:T | 3F8 (µg/mL) | % Specific Lysis |
|----------|-----|-------------|-----------------|
| LAN-1    | Normal | 25:1 | 2 | 52 | 72 |
| LAD      | Normal | 25:1 | 2 | 0 | 0 |
| LAD      | 100:1 | 10 | 0 | 0 |
| SKMel-1  | Normal | 100:1 | 2 | 70 | ND |
| LAD      | 100:1 | 2 | 1 | 1 |
| LAD      | 100:1 | 10 | 2 | 1 |

These results are representative of three similar studies. Abbreviation: ND, not done.
dependent inhibition of ADCC, with complete or near complete abrogation of ADCC at 5 to 10 μg/mL.

In contrast, three different anti-CD11a MoAbs (TS1/22, 2F12, G25.2) in concentrations up to 100 μg/mL had no effect on ADCC. A fourth anti-CD11a MoAb (R3.1) was inhibitory only at concentrations ≥25 to 50 μg/mL when SKMel-1 was the target, and at concentrations ≥50 μg/mL when LAN-1 was the target. This lack of effect of anti-CD11a MoAb may be explained by the low expression on melanoma of ICAM-1, which is a ligand for CD11a, and the absence of ICAM-1 on LAN-1, which was previously reported and which we documented using flow cytometry and the anti–ICAM-1 MoAb R1.1 (not shown).

We found variability in the ADCC inhibitory efficiency of different anti-CD11/CD18 MoAbs, a phenomenon described with non-ADCC adherence functions of PMNs. Among the anti-CD11/CD18 MoAbs assayed in our system, the anti-CD18 MoAbs were the most efficient inhibitors (R15.7 more than IB4 and TS1/18; Fig 1), and the anti-CD11b MoAbs LM2/1 and Mo1 were more inhibitory than OKM-1 and OKM-10 (not shown). Thus, OKM-1 in concentrations up to 100 μg/mL produced less than 20% inhibition of ADCC against LAN-1, and inhibited ADCC against SKMel-1 by 50% or more only when present at 12.5 μg/mL or greater. In comparison to LM2/1 or Mo1, OKM-10 was less inhibitory when LAN-1 was the target, but equally inhibitory when SKMel-1 was the target. The results with OKM-1 and, to a lesser degree, with OKM-10 suggested that nonspecific steric effects did not account for the sensitivity of ADCC to the anti-CD11/CD18 MoAbs. This point was reinforced by the normal ADCC that occurred in the presence of the anti-β-2-microglobulin MoAb BBM.1 in concentrations up to 100 μg/mL (not shown).

FcR requirements. Blocking MoAbs were used to identify the roles of the different FcR in 3F8-mediated PMN ADCC (Fig 2). The anti-FcRI MoAb 197 in concentrations up to 100 μg/mL had no effect on ADCC. This result was not unexpected because FcRI is present at very low density on PMN. In contrast, the anti-FcRII MoAb IV.3 and the anti-FcRIII MoAb 3G8 each completely abrogated ADCC at 1 μg/mL or less. Flow cytometry studies with anti-FcRII MoAb versus anti-FcRIII MoAb did not show cross competition (not shown), confirming prior reports of individual anti-FcR MoAb specificity, and suggesting that steric factors could not account for the respective ADCC blocking effects of IV.3 and 3G8. Thus, both FcRII and FcRIII appeared to be required for successful ADCC.

Because of evidence that the PI-linked FcRIII of PMN may not be critical for PMN function, including tumor cell kill, studies were performed to assess directly the require-
ment for FcRIII in 3F8-mediated PMN ADCC. Enzyme treatment significantly depleted PMN of FcRIII \( (P = 0.044) \), with little effect on the expression of non–PI-linked surface molecules (Table 2). In comparison to normal PMN, the FcRIII-deficient PMN performed poor ADCC in the presence of 3F8 (Table 2). These findings favored an FcRIII requirement for optimal lysis in this system.

Additional support for this conclusion came from studies using PMN from adults with PNH (Table 3). Immunophenotyping confirmed that these PMN, as reported, had very low expression of PI-linked surface molecules, including FcRIII and DAF. Similar to findings with PMN enzymatically depleted of FcRIII, PNH PMN were ineffective in ADCC as compared with normal PMN (Table 3).

**Effects of GM-CSF:** To gain further insight into the roles of FcR and the CD11/CD18 complex in 3F8-mediated PMN ADCC, studies were performed using GM-CSF. This cytokine enhances PMN ADCC\(^ {4,22,23} \) and has obvious potential clinical relevance. GM-CSF significantly increased CD11b \( (P < .001) \), CD11c \( (P = .007) \), and CD18 \( (P = .004) \) expression and, as expected, enhanced 3F8-mediated PMN ADCC (Table 4). GM-CSF produced a less than significant decrease in both FcRII and FcRIII expression, but did not appreciably change the density of other PMN surface molecules. The inclusion of GM-CSF in the ADCC assay did not alter the relative inhibitory effects of the anti-CD11/CD18 MoAbs, although higher concentrations of these MoAbs were required to inhibit ADCC (not shown). Thus, while anti-CD11a MoAbs had no effect on ADCC by GM-CSF–stimulated PMN, cytotoxicity curves (such as those in Fig 1) using MoAbs to CD11b, CD11c, and CD18 were shifted to the right in the presence of GM-CSF. These results were consistent with the possibility that GM-CSF enhances 3F8-mediated PMN ADCC at least partly via upregulation of CD11b, CD11c, and CD18.

![Table 2](image)

| Phenotype (% positive/mean fluorescence) | Untreated PMN | Elastase-Treated PMN | PI-PLC-Treated PMN |
|-----------------------------------------|--------------|----------------------|-------------------|
| MoAb                                    |              |                      |                   |
| IgG (control)                           | 0.3/7.05     | 0.9/7.54             | 1.0/7.98          |
| TS1/22 (CD11a)                          | 99.3/86      | 99.7/85              | 99.5/79           |
| OKM-1 (CD11b)                           | 99.7/639     | 99.7/554             | 99.7/647          |
| LeuM5 (CD11c)                           | 98.7/64      | 97.0/55              | 98.8/66           |
| TS1/18 (CD18)                           | 99.7/193     | 99.6/199             | 99.6/188          |
| A10 (DAF)                               | 76.9/39      | 54.8/35              | 13.2/27           |
| IV.3 (FcRIII)                           | 99.4/195     | 99.1/157             | 99.3/177          |
| 3G8 (FcRIII)                            | 97.9/1,038   | 98.6/246             | 98.1/241          |

| ADCC (% specific lysis)                 |                |                      |                   |
|-----------------------------------------|                |                      |                   |
| Target                                  |                |                      |                   |
| IMR-6                                   | 72             | 48                   | 28                |
| LAN-1                                   | 56             | 24                   | 18                |
| SKMel-1                                 | 37             | 16                   | 6                 |

PMN were incubated for 1 hour in medium alone, medium plus elastase (10 \( \mu \)g/mL),\(^ {40} \) or medium plus PI-PLC (1 U/mL), and were then immunophenotyped and tested in ADCC. Effector:target ratio, 100:1. The data are representative of three experiments.

![Table 3](image)

| Phenotype (% positive/mean fluorescence) | Normal PMN | PNH PMN |
|-----------------------------------------|------------|---------|
| MoAb                                    |            |         |
| IgG (control)                           | 2.0/5.7    | 2.1/5.4 |
| A10 (DAF)                               | 90.2/25    | 2.9/5.8 |
| 197 (FcR)                               | 3.8/7      | 10.3/8.3|
| IV.3 (FcRIII)                           | 99.9/101   | 99.8/89 |
| 3G8 (FcRIII)                            | 99.6/683   | 98.8/36 |

**ADCC (% specific lysis)**

| Target                                  | Normal PMN | PNH PMN |
|-----------------------------------------|------------|---------|
| IMR-6                                   | 50         | 26      |
| LAN-1                                   | 50         | 16      |
| SKMel-1                                 | 50         | 3       |

PMN from two adults with PNH were studied in parallel experiments with normal PMN. Representative results are shown here. Abbreviation: E:T, effector:target ratio.

**DISCUSSION**

We have defined PMN surface receptors critical for PMN ADCC of human solid tumor cells. In the presence of 3F8, an MoAb that has antitumor activity in patients,\(^ {4} \) ADCC is dependent on a physical interaction between PMN and \( G_{P}^{+} \) human neuroectodermal cells that does not involve phagocytosis but requires most subunits of the CD11/CD18 complex, FcRII, and the PI-linked FcRIII. Several of these features differ from those associated with PMN ADCC in model systems using heterologous antibodies and nonhuman or nonneoplastic target cells.

![Table 4](image)

| Phenotype (% positive/mean fluorescence) | Untreated PMN | GM-CSF-Treated PMN |
|-----------------------------------------|--------------|-------------------|
| MoAb                                    |              |                   |
| IgG (control)                           | 2.8/7.44     | 1.6/7.2           |
| TS1/22 (CD11a)                          | 99.5/66      | 99.8/72           |
| OKM-1 (CD11b)                           | 100/436      | 100/725           |
| LeuM5 (CD11c)                           | 97.9/49      | 99.7/78           |
| TS1/18 (CD18)                           | 99.9/132     | 99.6/223          |
| A10 (DAF)                               | 98.6/45      | 99.9/56           |
| 197 (FcR)                               | 13.2/7.8     | 6.1/9.5           |
| IV.3 (FcRIII)                           | 98.8/144     | 99.1/102          |
| 3G8 (FcRIII)                            | 98.9/397     | 99.1/301          |

**ADCC (% specific lysis)**

| Target                                  | Normal PMN | PNH PMN |
|-----------------------------------------|------------|---------|
| IMR-6                                   | 50         | 30      | 54     |
| LAN-1                                   | 100        | 49      | 79     |
| SKMel-1                                 | 100        | 34      | 50     |

PMN were incubated for 2 hours in medium with or without GM-CSF (2 ng/mL), washed, and immunophenotyped or tested in ADCC. In this representative study, GM-CSF upregulated CD11b, CD11c, and CD18 and enhanced 3F8-mediated PMN ADCC. Abbreviation: E:T, effector:target ratio.
The availability of LAD PMN allowed us to establish the importance of the CD11/CD18 complex in 3F8-mediated PMN ADCC. Inhibition studies using specific MoAbs showed that all subunits of the complex, except CD11a, were critical for normal PMN cytotoxicity with 3F8. Given the results with LAD PMN, the abrogation of 3F8-mediated PMN ADCC produced by MoAbs to CD18, the β subunit common to all three CD11 α subunits, might have been predicted. The same holds for the inhibitory effects of MoAbs to CD11b, which is the most abundant of the CD11 α subunits on PMN and has well-established myeloid cell adhesive functions. Our results suggest that either (1) PMN-target cell attachment via CD11b or CD11c is necessary but not sufficient for 3F8-mediated ADCC to proceed, or (2) in our system, when CD11b or CD11c is blocked, the other becomes nonfunctional. A redundancy of function among the CD11/CD18 molecules has previously been noted, and is supported, for example, by the relative structural homology between CD11b and CD11c.

No prior report has described the involvement of CD11/CD18 molecules in PMN ADCC of human solid tumor cells (as mediated by MoAbs or by heterologous antibodies). The sole previously reported study of ADCC by LAD PMN targeted herpes simplex virus-infected Chang liver cells. Findings in that study differed from our own in that defective ADCC was attributed to the absence of CD11a and CD11b, because anti-CD11a (TS1/22) MoAb alone or the combination of anti-CD11b (OKM-1) plus anti-CD18 (TS1/18) MoAbs blocked ADCC by normal PMN (anti-CD11b or anti-CD18 MoAb alone produced insignificant inhibition). The lack of effect of anti-CD11a MoAb on 3F8-mediated PMN ADCC is consistent with the low-to-absent expression of the CD11a ligand ICAM-1 on the melanoma and neuroblastoma targets. The known counter-receptors for CD11b and CD11c include iC3b, fibronectin, factor X, as well as ICAM-1; identification of the ligands for CD11b and CD11c in our system awaits further studies.

Our results with GM-CSF are consistent with an important role for CD11/CD18 in 3F8-mediated PMN ADCC, because GM-CSF enhancement of the latter occurred in conjunction with increased expression of CD11b, CD11c, and CD18. Although GM-CSF can affect the respiratory burst of PMN, two lines of evidence suggested to us that GM-CSF may act via CD11/CD18 in our system: (1) We had previously found that GM-CSF enhances 3F8-mediated ADCC by PMN with defective oxidative metabolism (obtained from patients with chronic granulomatous disease). The time-course of GM-CSF enhancement of PMN ADCC that we and others had observed was more consistent with its rapid upregulation of PMN CD11/CD18 than with the more delayed onset of its activation of PMN oxidative metabolism.

In addition to its effects on the CD11/CD18 complex, GM-CSF decreased PMN expression of FcRII and FcRIII, a previously reported phenomenon. Our studies cannot rule out the possibility that GM-CSF enhances 3F8-mediated PMN ADCC by non-CD11/CD18 effects, such as increasing the affinity of FcR or mobilizing nonoxidative cytolytic capacities.

Studies of the role of FcR in 3F8-mediated PMN ADCC underscored the importance of physical PMN-target attachment. Thus, anti-FcRII and anti-FcRIII MoAbs each efficiently inhibited ADCC. Furthermore, PMN enzymatically depleted of FcRIII and PNH PMN, which have low FcRII expression, were ineffective in ADCC as compared with normal PMN. The results suggest that, as with CD11b and CD11c, the separate involvement of each low-affinity FcR is necessary but not sufficient for optimal 3F8-mediated PMN ADCC. The current report is the first to document a requirement for both FcRII and FcRIII in PMN ADCC against human (or nonhuman) tumor or nonneoplastic targets. Our findings are noteworthy because, although Fc-FcR interactions are the well-established basis of ADCC, the issue has been clouded by the discovery that FcRIII is anchored to the plasma membrane of PMN by a PI moiety and may therefore have a limited capacity for signal transduction (see below).

A requirement for the PI-linked FcRIII in PMN ADCC is evident in some but not all model systems. Thus, PMN lyse murine hybridoma cells bearing antibody directed against FcRII, but not those bearing antibody against FcRIII. In contrast, PMN lyse chick erythrocytes coated with antibody directed against FcRII or FcRIII; heteroaggregates of anti-FcRIII and anti-2,4-dinitrophenyl antibodies mediate PMN destruction of 2,4,6-trinitrophenyl-modified RDM4 murine leukemia cells; and salivary PMN, which have very low expression of FcRIII, are ineffective in ADCC of herpes simplex virus-infected Chang liver cells. The latter two reports do not include data relating to other FcR, such as FcRII expression on salivary PMN or the effects on ADCC of anti-FcRII MoAb.

FeR requirements in PMN ADCC of human tumor cells have not been described before the present report. One attempt to do so was unsuccessful when PMN did not lyse JY human B-lymphoblastoid cells that were precoated with a murine IgG2a MoAb. This failure illustrates the difficulty in achieving ADCC of human tumor cells by unstimulated PMN; it also supports the hypothesis that PMN ADCC of human tumor cells, which are too large for phagocytosis by PMN and are relatively resistant to reactive oxygen species, involves cytotoxic mechanisms different from those in model systems using murine targets.

We have established that FcRIII is one of several PMN receptors required for 3F8-mediated PMN ADCC of human solid tumor (neuroectodermal) cells. It remains to be determined whether the PI-linked FcRIII on PMN is generating an intracellular signal to promote PMN cytotoxicity, or is only serving as a receptor for tight binding to MoAb-coated tumor cells, while signal transduction is effected by FcRII. Evidence supporting an active role for the PI-linked FcRIII independent of FcRII includes reports that PMN FcRIII can mediate exocytosis of granule...
proteins, production of superoxide anion, and elevation of cytosolic calcium derived from intracellular stores.

ACKNOWLEDGMENT

The authors thank Drs Hugo Castro-Malaspina, Nancy A. Kernan, and Lillian M. Reich for help in obtaining blood from patients with leukocyte defects; Dr Michael Tosi for helpful suggestions about elastase; Joon Kim for his expert technical assistance; Dr Glenn Heller for the statistical analyses; and Drs Michael W. Fanger, Alan M. Kremsky, M. Edward Medof, Patricia Rao, Jerome Ritz, Robert Rothlein, Timothy A. Springer, Robert F. Todd, Jay Unkeless, and Samuel D. Wright for generously providing MoAbs.

REFERENCES

1. Schulz G, Chereesh DA, Variki NM, Yu A, Staffileno LK, Reisfeld RA: Detection of ganglioside G, in tumor tissues and sera of neuroblastoma patients. Cancer Res 44:5914, 1984
2. Cheung NKV, Saarinen UM, Neely JE, Landmeier B, Donovan D, Coccia PF: Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res 45:2642, 1985
3. Miraldi F, Nelson AD, Kraly C, Ellery S, Landmeier B, Coccia PF, Strandjord SE, Cheung NKV: Diagnostic imaging of human neuroblastoma with radiolabeled antibody. Radiology 161: 413, 1986
4. Saarinen UM, Coccia PF, Gerson SL, Pelley R, Cheung NKV: Eradication of neuroblastoma cells in vitro by monoclonal antibody and human complement: Method for purging autologous bone marrow. Cancer Res 45:5969, 1985
5. Munn DH, Cheung NKV: Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma. Cancer Res 47:6600, 1987
6. Kushner BH, Cheung NKV: GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma. Blood 75:2408, 1989
7. Munn DH, Cheung NKV: Antibody-dependent antitumor cytotoxicity by human monocytes cultured with recombinant macrophage colony-stimulating factor. Induction of efficiency antibody-mediated antitumor cytotoxicity not detected by isotope release assays. J Exp Med 170:511, 1989
8. Cheung NKV, Lazarus H, Miraldi FD, Abramowsky CR, Kallick S, Saarinen UM, Spitzer T, Strandjord SE, Coccia PF, Berger NA: Ganglioside G, specific monoclonal antibody 3F8: A phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 5:1430, 1987
9. Steplewski Z, Sun LK, Shearnman CW, Ghrayeb J, Daddona P, Koprowski H: Biological activity of human-mouse IgGl, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity. Proc Natl Acad Sci USA 85:4852, 1988
10. Bruchelt G, Handgretinger R, Fierbeck G, Kimmig A, Dopfer R, Reisfeld RA, Treuner J, Niethammer D: Lysis of neuroblastoma cells by the ADCC-reaction: Granulocytes of patients with chronic granulomatous disease are more effective than those of healthy donors. Immunol Lett 22:217, 1989
11. Vaickus L, Biddle W, Cemerci D, Foon KA: Interferon gamma augments Lym-1–dependent, granulocyte-mediated tumor cell lysis. Blood 75:2408, 1990
12. Antman KS, Griftn JD, Elias A, Socinski MA, Ryan L, Cannistra SA, Oette D, Whitey M, Frei E III, Schnipper LE: Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med 319:593, 1988
13. Kaplan SS, Badfox RE, Wing JJ, Shaduck RK: The effect of recombinant human granulocyte macrophage colony-stimulating factor on neutrophil activation in patients with refractory carcinoma. Blood 73:636, 1989
14. Levy PC, Shaw GM, LoBuglio AF: Human monocyte, lymphocyte, and granulocyte antibody-dependent cell-mediated cytotoxicity toward tumor cells. J Immunol 123:594, 1979
15. Fuson EW, Shaw MW, Hubbard RA, Sugantharaj DG, Lamon EW: Antibody-dependent cell-mediated cytotoxicity by human lymphocytes. I. Comparison with polymorphonuclear leukocytes against erythrocyte and nucleated target cells. Exp Hematol 9:197, 1981
16. Dallegrisi F, Patrone F, Frumento G, Sacchetti C: Antibody-dependent killing of tumor cells by polymorphonuclear leukocytes. Involvement of oxidative and nonoxidative mechanisms. J Natl Cancer Inst 73:331, 1984
17. Borish L, Rocklin R: Effects of leukocyte inhibitory factor (LIF) on neutrophil mediated antibody-dependent cellular cytotoxicity. J Immunol 138:1480, 1987
18. Fabian I, Baldwin GC, Golde DW: Biocompatible granulocyte macrophage colony-stimulating factor enhances neutrophil cytolysis toward human leukemia cells. Leukemia 1:613, 1987
19. Galle RP, Zaghelbou J: Polymorphonuclear leukocytes in antibody-dependent cellular cytotoxicity. J Immunol 114:1047, 1975
20. Clark RA, Klebanoff SJ: Studies on the mechanism of antibody-dependent polymorphonuclear leukocyte-mediated cytotoxicity. J Immunol 119:1413, 1977
21. Hafeman DG, Lucas ZJ: Polymorphonuclear leukocyte-mediated, antibody-dependent, cellular cytotoxicity against tumor cells: Dependence on oxygen and the respiratory burst. J Immunol 123:55, 1979
22. Lopez AF, Williamson DJ, Gamble JR, Begley CG, Harlan JM, Klebanoff SJ, Waltersdorph A, Wang G, Clark SC, Vadas, MA: Recombinant human granulocyte-macrophage colony-stimulating factor stimulates in vitro mature human neutrophil and eosinophil function, surface receptor expression, and survival. J Clin Invest 78:1220, 1986
23. Perussia B, Kobayashi B, Rossi ME, Anegon I, Trinchieri G: Immune interferon enhances functional properties of granulocytes: Role of Fe receptors and effect of lymphotxin, tumor necrosis factor, and granulocyte-macrophage colony-stimulating factor. J Immunol 138:765, 1987
24. O'Donnell-Tormey J, DeBoer CJ, Nathan CF: Resistance of tumor cells in vitro to oxidative cytolysis. J Clin Invest 76:80, 1985
25. Kushner BH, Cheung NKV: The clinically effective monoclonal antibody 3F8 mediates nonoxidative lysis of human neuroectodermal tumor cells by polymorphonuclear leukocytes. Cancer Res 51:4865, 1991
26. Arnaout MA: Structure and function of the leukocyte adhesion molecules CD11/CD18. Blood 75:1037, 1990
27. Huizinga TWJ, Roos D, van dem Borne AEG Kr: Neutrophil Fe receptors: A two-way bridge in the immune system. Blood 75:1211, 1990
28. Selvaraj P, Rosse WF, Silber R, Springer TA: The major Fe receptor in blood has a phosphatidylinositol anchor and is deficient in paroxysmal nocturnal hemoglobinuria. Nature 333:565, 1988
29. Kinosita T, Medof ME, Silber R, Nussenzweig V: Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria. J Exp Med 162:75, 1985
30. Guyre PM, Graziano RF, Vance BA, Morganelli PM, Fanger MW: Monoclonal antibodies that bind to distinct epitopes on Fc-gammaRI are able to trigger receptor function. J Immunol 143:1650, 1989
31. Entman ML, Youker K, Shappell SB, Siegel C, Rothlein R,
Dreyer WI, Schmalstieg FC, Smith CW: Neutrophil adherence to isolated adult canine myocytes. Evidence for a CD18-dependent mechanism. J Clin Invest 85:1497, 1990

32. Rothlein R, Dustin ML, Marlin SD, Springer TA: A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1. J Immunol 137:1270, 1986

33. Arnaout MA, Todd RF III, Dana N, Melamed J, Schlossman SF, Colten HR: Inhibition of phagocytosis of complement C3- or immunoglobulin G-coated particles and of C3bi binding by monoclonal antibodies to a monococyte-granulocyte membrane glycoprotein (MoI). J Clin Invest 72:171, 1983

34. Wright SD, Rao PE, Van Voorhis WC, Craighney LS, Iida K, Talle MA, Westburg EF, Goldstein G, Silverstein SC: Identification of the C3bi receptor on human monocytes and macrophages by using monoclonal antibodies. Proc Natl Acad Sci USA 80:5699, 1983

35. Lanier LL, Arnaout MA, Schwartz R, Warner NL, Ross GD: p150,95, third member of the LFA-1/CR, polypeptide family identified by anti-LeuM5 monoclonal antibody. Eur J Immunol 15:713, 1985

36. Hogg N, Takaes L, Palmor DG, Selvendran Y, Allen C: The p150,95 molecule is a marker of human mononuclear phagocytes: Comparison with expression of class II molecules. Eur J Immunol 16:240, 1986

37. Kansas GS, Muirhead MJ, Dailey MO: Expression of the CD11/CD18, leukocyte adhesion molecule 1, and CD44 adhesion molecules during normal myeloid and erythroid differentiation in humans. Blood 76:2483, 1990

38. Knapp W, Dorken B, Rieber P, Schmidt RE, Stein H, von dem Borne AEG Kr: CD antigens 1989. Blood 74:14448, 1989

39. Sanchez-Madrigal F, Nagy J, Robbins E, Simon P, Springer TA: A human leukocyte differentiation antigen family with distinct alpha subunits and a common beta subunit: The lymphocyte function-associated antigen (LFA-1), the C3bi complement receptor (OKM1/Mac-1), and the p150,95 molecule. J Exp Med 158:1785, 1983

40. Miller LJ, Schwartz R, Springer TA: Regulated expression of the Mac-1, LFA-1, p150,95 glycoprotein family during leukocyte differentiation. J Immunol 137:2891, 1986

41. Sanchez-Madrid F, Krenszyk AM, Ware CF, Robbins E, Strominger JL, Burakoff SJ, Springer TA: Three distinct antigens associated with human T lymphocyte-mediated cytology: LFA-1, LFA-2, and LFA-3. Proc Natl Acad Sci USA 79:7483, 1982

42. Looney RJ, Ryan DH, Takahashi K, Fleit HB, Ahn HJ, Webb DSA, Mostowski HS, Gerrard TL: Cytokine-induced enhancement of ICAM-1 expression results in increased vulnerability of tumor cells to monocye-mediated lysis. J Immunol 146:3682, 1991

43. Gross N, Carrel S, Beck D, Favre S: Cell adhesion molecule expression and modulation on human neuroblastoma cells. Prog Clin Biol Res 366:293, 1991

44. Anderson DC, Miller LJ, Schmalstieg FC, Rothlein R, Springer TA: Contributions of the Mac-1 glycophosphatidyl inositol-linked receptor. J Immunol 137:1519, 1986

45. Huizinga TWJ, Kerst M, Nuyens JH, Vlug A, von dem Borne AEG Kr, Ross D, Tetteroo PAT: Binding characteristics of dimeric IgG subclass complexes to human neutrophils. J Immunol 142:2359, 1989

46. Tosi MF, Berger M: Functional differences between the 40 kDa and 50 to 70 kDa IgG Fc receptors on human neutrophils revealed by elastase treatment and antireceptor antibodies. J Immunol 141:2097, 1988

47. Alpers CE, Schlossman SF, Schall TJ, Springer TA: Functional and biochemical analysis of CD16 antigen on natural killer cells and granulocytes. J Immunol 137:2359, 1986

48. Sekaraj P, Carpen O, Hibbs ML, Springer TA: Natural killer cell and granulocyte Fe-gamma receptor III (CD16) differ in membrane anchors and signal transduction. J Immunol 143:3283, 1989

49. Stacke SA, Springer TA: Leukocyte integrin p150,95 (CD11c/CD18) functions as an adhesion molecule binding to a counter-receptor on stimulated endothelium. J Immunol 146:648, 1991

50. Kohl S, Springer TA, Schmalstieg FC, Laim SL, Anderson DC: Defective natural killer cytotoxicity and polymorphonuclear leukocyte antibody-dependent cellular cytotoxicity in patients with LFA-1/OKM-1 deficiency. J Immunol 133:2972, 1984

51. Weisbert RH, Kwan L, Golde DW, Gasson JC: Human CSF-GM primes neutrophils for enhanced oxidative metabolism in response to the major physiologic chemoattractants. Blood 69:18, 1987

52. Nathan CF: Respiratory burst in adherent human neutrophils: Triggered by colony-stimulating factors CSF-GM and CSF-G. Blood 73:301, 1989

53. Arnaout MA, Wang EA, Clark SC, Sieff CA: Human recombinant granulocyte-macrophage colony-stimulating factor increases cell-to-cell adhesion and surface expression of adhesion-promoting surface glycoproteins on mature granulocytes. J Immunol 78:597, 1986

54. Bickel AM, Hogg N: The effect of IFN-gamma and colony-stimulating factors on the expression of neutrophil cell membrane receptors. J Immunol 143:2295, 1989

55. Neuman E, Huleatt JW, Jack RM: GM-CSF increases synthesis and expression of CR1 and CR3 by human peripheral blood neutrophils. J Immunol 145:3325, 1990

56. Karpovsky B, Titus JA, Stephany DA, Segal DM: Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fc receptor antibodies. J Exp Med 160:1686, 1984

57. Ashkenazi M, Kohn SL: Reduced antibody-dependent cytotoxicity to herpes simplex virus-infected cells of salivary polymorphonuclear leukocytes and inhibition of peripheral blood polymorphonuclear leukocyte cytotoxicity by saliva. J Immunol 144:4781, 1990

58. Huizinga TWJ, van Kemenade F, Koenderman L, Dolman KM, von dem Borne AEG Kr, Tetteroo PAT, Roos D: The 40-kDa Fc receptor (FcRII) on human neutrophils is essential for the IgG-induced respiratory burst and IgG-induced phagocytosis. J Immunol 142:2365, 1989

59. Huizinga TWJ, Dolman KM, van der Linden KJM, Kleijer M, Nuijens JH, von dem Borne AEG Kr, Roos D: Phosphatidylinositol-linked FcRII mediates exocytosis of neutrophil granule proteins, but does not mediate initiation of the respiratory burst. J Immunol 144:1432, 1990

60. Crockett-Torabi E, Fantone JC: Soluble and insoluble immune complexes activate human neutrophil NADPH oxidase by distinct Fc-gamma receptor-specific mechanisms. J Immunol 145:3026, 1990

61. Kimberly RP, Ahlstrom JW, Click ME, Edberg JC: The glycosyl phosphatidylinositol-linked FcRIIPIm mediates transmembrane signaling events distinct from FcRII. J Exp Med 171:1239, 1990
Absolute requirement of CD11/CD18 adhesion molecules, FcRII and the phosphatidylinositol-linked FcRIII for monoclonal antibody-mediated neutrophil antihuman tumor cytotoxicity

BH Kushner and NK Cheung